Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (1790)	2/19/1999 10:56:00 PM
From: John Metcalf	Respond to of 10280

Not quite, wolfdog. SEPR has a convertible debt, 2mm shares at $125. They have $500mm in cash. The last cv debt (about 4mm share around $45?) was converted to shares a few months ago.

To: wolfdog2 who wrote (1790)	2/20/1999 9:29:00 AM
From: sam	Read Replies (2) \| Respond to of 10280

Actually, the stock is no where near priced for perfection -- yet. With the earnings growth projected, this stock could legitimately be trading much, much higher than 120. Even if it misses by 20%, the stock could still sky rocket. And that's exactly why I hope to be establishing a large position very soon. Another reason? I watched every trade the last couple of days and I can assure you that the "selling" wasn't institutional, but rather small-time shorters out of Island (and the market makers who love such volatility). The question is -- can it successfully transition from a drug developer to a drug seller (like Amgen and AGPH). At this point, I wouldn't bet that it won't. But that's just me. I have a strong feeling that this stock is gonna be a lot of fun. ;)